Intellia Therapeutics(NTLA)
Focus: Intellia Therapeutics is a public biotechnology company focused on in vivo CRISPR-based therapeutic gene editing, targeting rare genetic diseases with significant unmet medical needs.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
21-41 this month
Contracting — net -41 jobs in 30d
6 added, 47 removed. Active reduction in progress.
Should You Work at Intellia Therapeutics?
AI assessmentHigh-growth, high-risk opportunity best suited for scientists and early-career professionals seeking cutting-edge gene editing experience, but with material execution risk.
Why Work Here
- Work on cutting-edge CRISPR gene editing technology at a public company with multiple Phase 3 programs advancing toward potential approvals
- Strong H1B sponsorship (9 approvals, 0 denials in 2023) enables international talent recruitment
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$36M
Pipeline & Clinical Trials
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyClinical Trials (1)
NCT05697861Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
N/AHelp build intelligence for Intellia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.